Increase in generic competition for Temozolamide has meant the addressable generic market is now only $200m approx. Volume of scripts has probably remained steady but heavy discounting results in the decline in $value. Use of Temozolamide for extended indications is possible in the future also as there are a significant number of clinical trials combining it with other treatments for indications other than brain cancers.
Even a modest slice of the market will provide a significant double digit percentage growth in revenue. The current market cap of $37m belies where IDT will be next financial year.
Ann: Generics Sales Update, page-8
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IDT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
0.010(8.70%) |
Mkt cap ! $53.69M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 13.0¢ | 12.0¢ | $99.94K | 818.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 320 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 53148 | 2 |
View Market Depth
| Last trade - 15.48pm 09/08/2024 (20 minute delay) ? |
| IDT (ASX) Chart |